Proto-oncogenic H-Ras, K-Ras, and N-Ras are involved in muscle differentiation via phosphatidylinositol 3-kinase

Cell Res. 2010 Aug;20(8):919-34. doi: 10.1038/cr.2010.92. Epub 2010 Jul 6.

Abstract

Oncogenic H-Ras G12V and its variants have been shown to inhibit muscle differentiation. However, the role of proto-oncogenic Ras (c-Ras) in muscle differentiation remains unclear. The active GTP-bound form of Ras has been known to associate with diverse effectors including Raf, phosphatidylinositol 3-kinase (PI3K), Ral-GDS, and other molecules to transmit downstream signals. We hypothesize that c-Ras may stimulate muscle differentiation by selectively activating PI3K, an important mediator for muscle differentiation. In our experiments, inhibition of c-Ras by farnesyltransferase inhibitors and a dominant negative form of H-Ras (Ras S17N) suppressed muscle differentiation. Consistently, individual knockdown of H-Ras, K-Ras, and N-Ras by siRNAs all blocked muscle differentiation. Interestingly, we found that c-Ras preferentially interacts with PI3K rather than its major binding partner c-Raf, during myogenic differentiation, with total c-Ras activity remaining unchanged. PI3K and its downstream myogenic pathway, the Nox2/NF-kappaB/inducible nitric oxide synthase (iNOS) pathway, were found to be suppressed by inhibition of c-Ras activity during differentiation. Furthermore, expression of a constitutively active form of PI3K completely rescued the differentiation block and reactivated the Nox2/NF-kappaB/iNOS pathway in c-Ras-inhibited cells. On the basis of our results, we conclude that contrary to oncogenic Ras, proto-oncogenic H-Ras, K-Ras, and N-Ras are directly involved in the promotion of muscle differentiation via PI3K and its downstream signaling pathways. In addition, PI3K pathway activation is associated with a concurrent suppression of the otherwise predominantly activated Raf/Mek/Erk pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Differentiation
  • Cell Line
  • Farnesol / analogs & derivatives
  • Farnesol / pharmacology
  • Membrane Glycoproteins / metabolism
  • Muscle Development*
  • Myocardium / cytology
  • NADPH Oxidase 2
  • NADPH Oxidases / metabolism
  • NF-kappa B / metabolism
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type II / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Proto-Oncogene Proteins p21(ras) / metabolism*
  • Proto-Oncogene Proteins p21(ras) / physiology
  • RNA Interference
  • RNA, Small Interfering / metabolism
  • Rats
  • Salicylates / pharmacology
  • Signal Transduction

Substances

  • Membrane Glycoproteins
  • NF-kappa B
  • RNA, Small Interfering
  • Salicylates
  • farnesylthiosalicylic acid
  • Nitric Oxide
  • Farnesol
  • Nitric Oxide Synthase Type II
  • Cybb protein, rat
  • NADPH Oxidase 2
  • NADPH Oxidases
  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins p21(ras)